Even though there were no significant associations between genetically proxied TYK2 inhibition and risk of different cancers after correction for multiple comparison, three malignant neoplasms, including malignant neoplasm of prostate, male genital organs, and breast showed consistent suggestive positive associations with the TYK2 loss-of-function mutation in UK Biobank and FinnGen (Supplementary Table S9). This evidence concerns the gene TYK2 and prostate neoplasm.